PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells

Despite reports on the efficacy of proprotein convertase subtilisin-Kexin type 9 (PCSK9) inhibitors as a potent lipid-lowering agent in various large-scale clinical trials, the anti-atherogenic properties of PCSK9 inhibitors in reducing PCSK9 and atherogenesis biomarkers via the NF-ĸB and eNOS pathw...

Descripción completa

Detalles Bibliográficos
Autores principales: Zulkapli, Rahayu, Muid, Suhaila Abd, Wang, Seok Mui, Nawawi, Hapizah
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049668/
https://www.ncbi.nlm.nih.gov/pubmed/36982171
http://dx.doi.org/10.3390/ijms24065098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049668/
https://www.ncbi.nlm.nih.gov/pubmed/36982171
http://dx.doi.org/10.3390/ijms24065098

Ejemplares similares